P/E ratio for Lifecore Biomedical (LFCR)
P/E ratio as of May 2024 (TTM): -1.97
According to Lifecore Biomedical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.96791. At the end of 2022 the company had a P/E ratio of -2.59.
P/E ratio history for Lifecore Biomedical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.59 | -55.46% |
| 2021 | -5.81 | -6.93% |
| 2020 | -6.24 | -79.64% |
| 2019 | -30.7 | -304.56% |
| 2018 | 15.0 | -62.56% |
| 2017 | 40.0 | -227.56% |
| 2016 | -31.4 | -225.74% |
| 2015 | 24.9 | 11.69% |
| 2014 | 22.3 | 23.69% |
| 2013 | 18.1 | 40.39% |
| 2012 | 12.9 | -55.73% |
| 2011 | 29.1 | -16.94% |
| 2010 | 35.0 | 57.55% |
| 2009 | 22.2 | 51.84% |
| 2008 | 14.6 | 50.59% |
| 2007 | 9.71 | -62.95% |
| 2006 | 26.2 | -18.84% |
| 2005 | 32.3 | -19.74% |
| 2004 | 40.2 | -93.89% |
| 2003 | 659 | -3724.5% |
| 2002 | -18.2 | 127.88% |
| 2001 | -7.98 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.